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Introduction: To identify new therapeutic approaches in malignant
mesothelioma (MM), we examined the expression and activation of
receptor tyrosine kinases (RTKs) and the effects of specific RTK
inhibitors and the mammalian target of rapamycin (mTOR) inhibitor
rapamycin; the latter being of special interest in MM given the
recent linkage between NF2 loss and mTOR activation.
Methods: We performed a screen for mutated or activated RTKs in
14 MM cell lines and 70 primary tumors. Expression of phosphor-
ylated RTKs was analyzed by Western blotting and a membrane-
based antibody array in normal growth conditions and after treat-
ment by specific inhibitors. MET and epidermal growth factor
receptor (EGFR) mutations were screened by sequencing. MET,
hepatocyte growth factor, insulin-like growth factor 1 receptor, and
EGFR expression were studied by Western blotting, immunohisto-
chemistry, enzyme-linked immunosorbent assay, and by Affymetrix
expression microarrays.
Results: Profiling of the phosphorylation status of 42 RTKs showed
prominent coactivation of MET and EGFR in 8 of 14 (57%) MM
cell lines. MET, EGFR, and insulin-like growth factor 1 receptor
were the main RTKs activated after mTOR inhibition and contrib-
uted to AKT feedback activation. Knockdown of MET by RNA
interference inhibited not only the phosphorylation of MET but
also that of EGFR. Conversely, stimulation with hepatocyte
growth factor increased both phospho-MET and phospho-EGFR.
The combination of PHA-665752 and the EGFR inhibitor, erlo-
tinib, suppressed cell growth more than either agent alone in
three of six cell lines tested. Finally, combinations of rapamycin
and different RTK inhibitors were more active than either drug
alone in 12 of 13 cell lines.
Conclusion: Combination targeting of kinase signaling pathways is
more effective than single agents in most MM.
Key Words: Tyrosine kinase inhibitor, Cross-activation, mTOR
inhibitor, Combination therapy.
(J Thorac Oncol. 2011;6: 864–874)
Malignant mesothelioma (MM) is strongly associatedwith asbestos exposure1 and is diagnosed in 3000
individuals annually in the United States.2 Median survival
time for untreated patients ranges from 4 to 12 months.3,4
Surgery combined with postoperative radiotherapy and che-
motherapy (“multimodality therapy”) has shown benefit in
selected patients presenting with early-stage disease,5–8 but
for most patients, new treatment approaches are badly
needed. New agents targeting tyrosine kinases (TKs), in
particular receptor TKs, may be candidate drugs in MM
based on reports of the expression of several receptor tyrosine
kinases (RTKs) in this cancer.9–13 In MM, constitutive acti-
vation of phosphoinositide-3 kinase/Akt (PI3/AKT) is fre-
quent and contributes to the malignant phenotype,14,15 also
supporting a role for signaling from RTKs through PI3/AKT
in this cancer. Immunohistochemical studies,9,16 proteomics
studies,17 or Western blot9,16–20 have implicated multiple
RTKs in MM, including EGFR,9,16–20 MET,9,11,13,21 PDG-
FRA,16 PDGFRB,16 and insulin-like growth factor 1 receptor
(IGF1R).18–20 Coexpression of RTKs is also described:
EGFR and MET protein are coactivated in MM cell lines17,21
with a coexpression of hepatocyte growth factor (HGF) and
MET in 38% of cases,9 whereas EGFR and PDGFRB coex-
pression was described in MM tumors.16 These observations
may explain the disappointing results obtained with single-
agent RTK inhibitors. For instance, pharmacologic inhibitors
of MET alone do not show broad activity against MM cell
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Statement of Translational Relevance: Pleural malignant mesothelioma
(MM) cell lines frequently show coactivation of several receptor tyrosine
kinases (RTK), with expression of phospho-MET and phospho-EGFR
being most frequent. Herein, we present evidence of cross-activation
between these two RTKs and improved activity for combined EGFR and
MET inhibition in a subset of MM lines. Similarly, we find that different
RTKs can contribute to the AKT activation resulting from mTOR
inhibition in MM cell lines. Because of the involvement of multiple
RTKs in MM, individually tailored combination therapy may be neces-
sary to effectively suppress cell growth using inhibitors of RTKs and
mTOR.
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lines,22,23 and it has been shown that single-agent EGFR
inhibition is clinically ineffective in patients with MM, de-
spite high expression of EGFR.24,25
NF2 deletion, seen in more than 50% of mesothelio-
mas, has recently been causally associated with activation of
the mammalian target of rapamycin (mTOR) pathway in both
MM and schwannomas.26,27 Indeed, NF2 syndrome tumors
(schwannomas) and NF2-deficient cells demonstrate elevated
mTOR complex 1 (mTORC1). Furthermore, Lo´pez-Lago et
al.26 have shown that NF2-negative cell lines are sensitive to
rapamycin. Nevertheless, the inhibition of the mTOR path-
way by rapamycin is often associated with AKT feedback
activation in tumor cell lines. This paradoxical AKT activa-
tion was originally found to be due to release of feedback
inhibition on IGF1R signaling but can be mediated by other
RTKs as well.28,29
To better understand the role of RTKs in MM, we
performed a screen for phosphorylated RTKs in a MM cell
line panel, in normal growth conditions, and after treatment
with the mTOR inhibitor rapamycin. We report herein fre-
quent coactivation of EGFR and MET in MM, due in part to
cross-activation, imparting sensitivity to combined EGFR
and MET inhibition in approximately 50% of cell lines. We
also find that different RTKs can contribute to feedback
activation of AKT caused by mTOR inhibition in MM,
imparting sensitivity to combinations of rapamycin with dif-
ferent RTK inhibitors.
MATERIALS AND METHODS
Cell Culture
We used 14 MM cell lines and two immortalized
human mesothelial cell lines. Given that the Meso 34 and
Meso 37 cell lines are clonally related (results not shown) and
gave essentially identical results in all experiments, they were
counted as one in some experiments. H28, H2452, VAMT,
JMN, H2052, H2373, H-Meso, and H-Meso1A were cultured
in RPMI1640 supplemented with 10% fetal bovine serum,
100 units/ml penicillin, and 100 g/ml streptomycin in a
humidified atmosphere of 5% CO2 at 37°C. Meso-9 and
Meso-10 were cultured in RPMI1640 with 25 mM HEPES,
ITSS, 15% fetal bovine serum, 100 units/ml penicillin, and
100 g/ml streptomycin. The two immortalized nontumori-
genic mesothelial cell lines (Met5A and LP9) were cultured
in 199 Earl’s BSS with L-glutamine, 1.25 g/liter NaHCO3,
3.3 nM EGF, 400 nM hydrocortisone, 870 nM zinc-free
insulin, and 20 mM HEPES. For stimulation studies with
HGF or EGF, we used recombinant human HGF (R&D
Systems, Minneapolis, MN) or human EGF (Calbiochem,
Darmstadt, Germany). Cells were starved of growth factors
by incubation in serum-free medium for 24 hours. Cells were
then cultured in growth medium with 100 ng/ml of HGF or
EGF for 12 hours.
Drugs
PHA-665752 was a gift of Pfizer Pharmaceuticals (La
Jolla, CA). Erlotinib was a gift from Dr. William Pao. Stock
solutions were prepared in DMSO and stored at 20°C.
MK-0646 was a gift of Merck (Merck & Co, NJ) and was
conserved in phosphate-buffered saline at 4°C. The drugs
were diluted in fresh medium before use.
Cell Proliferation Assay
Growth inhibition assay were quantified using a mod-
ified MTT (3-[dimethylthiazol-2-yl]-2,5-diphenyl tetraso-
dium bromide) colorimetric assay (Promega, Madison, WI).
Cells were plated at a density of 1  104/well in a 96-well
plate at 37°C in a 5% humidified atmosphere. After 72 hours,
15 l MTT was added to each well, and incubation was
continued at 37°C for 4 hours. Then, 100 l stabilization/stop
solution was added to each well, and the plate was transferred
to room temperature for 1 hour. Absorbance values at 570
and 630 nm were measured with a microplate reader, and the
reduction value (absorbance at 570 nm—absorbance at 630
nm) was calculated. Each assay was performed in triplicate,
and the average absorbance was calculated.
Proteome Profiler Array
We extracted protein from MM cells using T-PER
Tissue Protein Extraction Reagent and Halt Protease Inhibitor
Cocktail Kit (Pierce, Rockford, IL). We used the Human
phospho-Receptor Tyrosine Kinase Array (R&D Systems) to
identify the relative levels of phosphorylation of 42 different
RTKs. We added 1.5 ml of Array Buffer 1 for blocking,
placed one array into each well, and incubated for 1 hour.
Array Buffer 1 was replaced by the diluted lysates containing
500 g protein. They were incubated overnight at 4°C, and
then we removed each array and placed into individual plastic
containers with Wash Buffer. The detection antibody was
added to each well, after three washes. Each array was
incubated for 2 hours at room temperature and then examined
using ECL Western blotting detection reagents and analysis
system (Amersham Biosciences, Little Chalfont, Bucking-
hamshire, UK) after three washes.
Western Blotting
Proteins were extracted using T-PER Tissue Protein
Extraction Reagent and Halt Protease Inhibitor Cocktail Kit
(Pierce). Proteins (20 g) were electrophoresed on a 4 to 12%
Tris-Glycine Gel (Invitrogen, Carlsbad, CA) and transferred
to a polyvinylidene fluoride membrane. Antibodies used for
Western blotting are listed in Supplementary Table 1
(http://links.lww.com/JTO/A74).
Affymetrix Gene Chip Microarray Data
We examined MET and HGF gene expression in Af-
fymetrix Gene Chip data from our previous study of MM
tumor samples.30 We also examined 14 MM cell lines using
Affymetrix U133Plus 2.0 arrays. Total RNA was extracted
from 14 MM cell lines and two immortalized mesothelial cell
lines using TRIzol (Invitrogen) and further purified using
RNeasy kit (Qiagen, Valencia, CA). All microarray hybrid-
ization and scanning steps were done in the MSKCC Genom-
ics Core Laboratory. Briefly, total RNA was converted to
double-stranded complementary DNA (cDNA) with oligo
d(T) primers and reverse transcription before in vitro tran-
scription with biotinylated UTP and CTP. The resulting
biotinylated cRNA was then fragmented and hybridized for
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16 hours at 45°C to the Affymetrix U133Plus 2.0 arrays
(Santa Clara, CA).
DNA Sequence Analysis
Sequencing was performed from cDNA or genomic
DNA. For the former, 1 g total RNA samples were retro-
transcribed into first-strand cDNA by using the SuperScript
Fist-Strand Synthesis System following the manufacturer’s
protocol (Invitrogen). Polymerase chain reaction amplifica-
tion of cDNA or genomic DNA was done with HotStart
master mix (Qiagen). Direct sequencing of polymerase chain
reaction products was performed in the MSKCC Genomics
Core Laboratory using the Big-Dye Terminator kit (Applied
Biosystems, Foster City, CA).
HGF and EGF Detection in Cell Supernatants
Confluent cells grown in serum-containing medium
were washed with phosphate-buffered saline and cultured in
serum-free medium for 24 hours. The cells were then incu-
bated in fresh serum-free medium for another 48 hours. The
medium was collected and centrifuged. The supernatant was
analyzed using the Human HGF and EGF Immunoassay Kits
(Quantikine, R&D Systems, Inc., Minneapolis, MN). All
samples were run in triplicate. Color intensity was measured
at 450 nm using a spectrophotometric plate reader.
RNA Interference Studies
Two MET siRNAs were used in this study, Hs_MET_
5HP Validated siRNA (siRNA1) and Hs_MET_10HP Validated
siRNA (siRNA2) (Qiagen). Control transfection was performed
in parallel using Allstars Negative Control siRNA (Qiagen). The
siRNAs were transfected into MM cells with Lipofectamine
(Invitrogen) using the manufacturer’s recommended conditions.
Proteins were extracted 72 hours after siRNA transfection.
Enzyme-Linked Immunosorbent Assay
The human HGF enzyme-linked immunosorbent assay
kit was obtained from R&D systems and performed accord-
ing to manufacturer’s instructions. Lysates were obtained
after overnight serum starvation; 25 g of total protein was
used for each cell lines, in triplicate.
Statistical Analysis
For semiquantitative analyses, the images of Proteome
Profiler Array blots and Western blots were analyzed using
NIH Image. For the Proteome Profiler Array results, the ratio
to controls was calculated for each phosphorylated RTK in
each array experiment, and a heatmap was derived. For the
Western blotting results, the ratio to H28 was also calculated.
The Spearman rank correlation was calculated to assess the
correlation between the data.
RESULTS
Coexpression and Coactivation of MET and
EGFR in MM
Fourteen MM cell lines were assayed for the level of
phosphorylation of 42 RTKs using Proteome Profiler Arrays
(Figure 1). Overall, 10 of 14 MM cell lines expressed higher
levels of phosphorylated EGFR than controls, and 6 of 14 MM
cell lines show moderate to high expression of phospho-MET
(Meso 9, H28, H2373, H2452, H-Meso, and Meso 34) (Figure
1 and Supplementary Figure 1, http://links.lww.com/JTO/A75).
Thus, 6 of 14 lines (43%) coexpressed phosphorylated
MET and EGFR. Expression of other phosphorylated
RTKs was sporadic and uncommon. H-Meso and Meso 10
showed moderate expression of phosphorylated IGF-1R.
The latter was also expressed to a lesser degree in Meso 56
and 211H. RET and Erbb2 were also moderately activated
in some cell lines.
After EGFR, MET is the most frequently activated
RTK in MM cells. Therefore, we investigated the MET
pathway in MM cell lines. Total MET was highly expressed
by enzyme-linked immunosorbent assay in the H2373,
H-Meso, H2452, and H28 cell lines (Supplementary Figure 2,
http://links.lww.com/JTO/A76). In contrast, it was only mod-
estly expressed in the cell lines that showed no phosphory-
lation of MET in the Proteome Profiler Array hybridizations,
such as the 211H and Meso 56 cell lines. We then used
Affymetrix Gene Chip expression data to assess the 14 MM
cell lines for HGF/MET coexpression that could form the
basis for an autocrine loop. The transcript levels were com-
pared with those in two immortalized nontumorigenic meso-
thelial cell lines (LP9 and Met5A). Compared with immor-
talized mesothelial cell lines LP9 and Met5A, MET transcript
levels in MM cell lines were higher in 13 of 14 cell lines
(93%) relative to the former and in 9 of 14 lines (64%)
relative to the latter cell line (Supplementary Figure 3,
http://links.lww.com/JTO/A77). We should note that the
Met5A, although whereas commonly used experimentally as
nontumorigenic mesothelial cell line, shows widespread
genomic copy number aberrations (results not shown). HGF
transcript levels were significantly elevated in only one cell
line (7%) (JMN), compared with immortalized normal me-
sothelial cells. In 13 of 14 (93%) cell lines, HGF transcript
levels were significantly lower than in the LP9 cell line. Thus,
there was significantly high coexpression of the MET and
HGF genes in one cell line (JMN), when compared with
immortalized normal mesothelial cells. On the basis of this
FIGURE 1. Heatmap of expression of 13 most frequently
expressed phosphorylated receptor tyrosine kinases in malig-
nant mesothelioma. Raw data images for six lines are pro-
vided in Supplementary Figure 1.
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analysis, we next compared HGF production by the JMN line
with that of seven other MM cells (H2373, H-Meso, VAMT,
Meso 10, Meso56, H-Meso1A, and H28) using Immunoassay
kits as described in Materials and Methods section. Only
JMN exhibited autocrine HGF production (340 pg/ml in
JMN, versus 50 pg/ml in other cell lines). We also exam-
ined EGF production by these eight MM cell lines, but no
EGF was detected in the supernatants. Based on Affymetrix
SNP array data, none of the 14 MM cell lines showed focal
or high level EGFR or MET amplification, and focal gains of
these genes are also not seen in MM tumors.
Coexpression of MET and HGF in a Subset of
Primary MM
To assess how often the conditions for autocrine MET
activation in MM might occur in vivo, we examined the
coexpression of MET and HGF at both the mRNA and
protein levels, in 99 MM tumors, by Affymetrix Gene Chip
Microarray and immunohistochemistry (IHC), respectively.
In Affymetrix U133A expression data, 6 of 99 (6%) MM
cases showed elevation of both HGF and MET transcripts
(Supplementary Figure 4, http://links.lww.com/JTO/A78).
By IHC on tissue microarrays, 56 of 118 (47%) of MM cases
were immunoreactive for HGF, of which 20 (17%) showed
strong immunoreactivity (2 or more) (Supplementary Fig-
ure 5A, http://links.lww.com/JTO/A79). All showed cyto-
plasmic granular or vesicular staining. By IHC, 105 of 118
(89%) cases were immunoreactive for MET, of which 64 of
118 (54%) showed strong immunoreactivity (2 or more).
Nevertheless, only 13 of 118 (11%) cases showed strong
immunoreactivity for both HGF and MET (Supplementary
Figure 5B, http://links.lww.com/JTO/A80). Based on these
data, approximately 10% of MM show high-level HGF and
MET coexpression that could form the basis for autocrine
activation, a proportion similar to that seen in cell lines (1/13).
Cross-Activation of MET and EGFR in MM
Given the frequent coexpression and coactivation of
MET and EGFR in MM, we looked for evidence of cross-
activation between these two RTKs. First, we examined
target inhibition by PHA-665752 in three cell lines (H-Meso,
211H, and Meso 9). Phosphorylation of RTKs 12 hours after
administration of PHA-665752 at the respective IC50 con-
centrations was measured using Proteome Profiler Arrays
(Supplementary Figure 6, http://links.lww.com/JTO/A81). In
all three lines, PHA-665752 completely inhibited MET phos-
phorylation (Figure 2). At these relatively high IC50 concen-
trations, PHA-665752 also inhibited EGFR phosphorylation
in all three lines, either partially (H-Meso and Meso 9) or
almost completely (211H) (Figure 2). By Western blot, stim-
ulation by EGF also increased p-MET in Meso 37 and 211H
cell lines and, vice versa, stimulation by HGF increased
p-EGFR, without effects on total EGFR or total MET (Figure
3). Conversely, we examined the effect of knockdown of
MET by siRNA on expression of phosphorylated EGFR in
two other MM cell lines (H-Meso and VAMT). Knockdown
of MET with two different siRNAs decreased phosphorylated
EGFR in both cell lines (Figure 4) and was also associated
FIGURE 2. In the H-Meso, 211H,
and Meso 9 cell lines, the MET TKI
PHA-665752 at the IC50 concen-
tration for each line reduces phos-
phorylation of both MET and EGFR.
Bar graphs generated from the raw
data images using Image J soft-
ware; raw data images are pro-
vided in Supplementary Figure 6.
MET, HGF receptor; TKI, tyrosine
kinase inhibitor; IC50, inhibitory
concentration 50%; EGFR, epider-
mal growth factor receptor.
FIGURE 3. Phosphorylated MET and
EGFR in the Meso 37 cell line 12 hours
after administration of HGF (100 ng/ml).
HGF triggered phosphorylation not only
of MET but also of EGFR. Nevertheless,
12 hours after administration of EGF
(100 ng/ml) only phosphorylated EGFR
was increased. MET, HGF receptor; EGFR,
epidermal growth factor receptor; HGF,
hepatocyte growth factor; EGF, epider-
mal growth factor.
Journal of Thoracic Oncology • Volume 6, Number 5, May 2011 Coactivation of RTKs in MM
Copyright © 2011 by the International Association for the Study of Lung Cancer 867
with significant growth inhibition (not shown). Neither MET
siRNA had any effect on total EGFR.
Activation of MET and EGFR in MM is Not Due
to Somatic Mutations
The 14 MM cell lines and 70 tumor samples were
examined for mutations in the semaphorin, juxtamembrane,
and kinase domains of MET. Two cell lines contained MET
sequence alterations, both in the juxtamembrane domain,
both previously reported as SNPs: VAMT contained T1010I
and Meso-9 contained R988C. Meso-9 showed strong expres-
sion of phosphorylated MET, but the VAMT cell line showed
only minimal phosphorylation of MET. We found nonsyn-
onymous coding sequence alterations in 6 of 70 MM tumor
samples, including T1010I in three cases, and G1137A,
V136I, and S203T in one sample each (data not shown).
Examination of matched normal tissues indicated that all
three T1010I and the V136I were germline polymorphisms.
For the remaining two novel nonsynonymous sequence alter-
ations, G1137A and S203T, located in the MET semaphorin
and kinase domains, respectively, we were unable to confirm
a somatic origin due to unavailability of matching normal
DNA. We also sequenced the kinase domain of EGFR in the
14 cell lines and uncovered no mutations. These sequencing
results indicate that the frequent activation of MET and
EGFR in MM is not due to somatic mutations.
Various RTKs are Activated on mTOR
Inhibition in MM Cells
Next, we assessed the effects of mTOR inhibition in MM
cell lines, both to better understand RTK signaling in MM (by
identifying which RTKs may be involved in rapamycin-induced
AKT activation) and to evaluate it as a therapeutic target given
its reported activation caused by NF2 loss in MM. Indeed, 6 of
13 mesothelial cell lines did not show NF2 expression by
Western blot, and this was correlated with lower mRNA
expression in Affymetrix array data (p  0.01) (Supplemen-
tary table 2, http://links.lww.com/JTO/A74). We performed
Human phospho-Receptor Tyrosine Kinase Arrays (R&D
Systems) on 13 MM cell lines after treatment with rapa-
mycin 0.1 nM. This showed increased p-RTK expression
in seven cell lines. P-EGFR expression increased in two
cell lines (Meso 10 and H2052; Figure 5), p-MET in-
creased in four lines (Meso 9, H28, Meso 34, and H-Meso
1A; Figure 5), p-IGF-1R increased in two lines (211H and
Meso 10) (Figure 5), and p-PDGFR appeared in one cell
line (Meso 56) (not shown). For three cell lines, we
observed a decrease in p-EGFR or p-MET (JMN, H2452,
and H2373), and no changes were observed in two cell
lines (VAMT and H-Meso). Furthermore, by Western blot,
we show that rapamycin 0.1 nM induces AKT activation in
10 of 13 cell lines, in 10% FCS (Figure 6). This feedback
activation disappears in medium lacking FCS (FCS)
(Figure 6). These results suggest that rapamycin induces
AKT activation in most MM cell lines by loss of negative
feedback at the level of various RTKs.
Combination Targeting of RTK Signaling in
MM
On the basis of the observed EGFR-MET coactivation
and cross-activation, we evaluated combination therapy with
MET and EGFR inhibitors in six MM cell lines (JMN,
H-Meso, Meso9, Meso10, VAMT, and 211H) (Figure 7). The
six MM cell lines were treated with increasing concentrations
of erlotinib alone, PHA-665752 alone, or the two drugs in
combination. Erlotinib had no activity in MM cell lines (IC50
10 M) except in JMN (IC50: 10 M). When the two
drugs were used in combination, the IC50 was significantly
shifted relative to PHA-665752 alone in the JMN, Meso 10,
and Meso 9 cell lines. In H-Meso, VAMT, and 211H, the
combination did not change the IC50s significantly. To con-
firm combined target inhibition and to look for inhibition of
downstream signaling after combination tyrosine kinase in-
hibitor (TKI) therapy, we performed Western blotting in four
of these six cell lines 6 hours after administration of MET
inhibitor alone (10 M), of the EGFR inhibitor alone (10
M), or of the combination (Figure 8). In all four lines, the
combination of the two inhibitors showed a synergistic effect
on levels of phosphorylated MET and EGFR in comparison
with either alone. In the two cell lines sensitive to the
combination therapy (JMN and Meso 9), the drug combi-
nation also decreased both p-AKT and p-ERK. In contrast,
the combination did not reduce p-AKT and p-ERK at all in
the H-Meso cell line and only slightly in the VAMT line
(Figure 8).
FIGURE 4. Knockdown of MET by
siRNAs decreased phosphorylated
EGFR, without affecting levels of
total EGFR. MET, HGF receptor;
SiRNA, short interfering RNA; EGFR,
epidermal growth factor receptor.
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Finally, because AKT feedback activation occurs in
MM cell lines after treatment with rapamycin, we examined
the effects of RTK inhibitors on cell proliferation in combi-
nation with rapamycin. When rapamycin is given alone,
although not reaching an IC50 in all cases, most of the cell
lines show a statistically significant decrease of cell prolifer-
ation at 0.1 nM or 1 nM compared with control (Supplemen-
tary Table 2, http://links.lww.com/JTO/A74). Cells were cul-
tured for 72 hours with increasing concentrations of erlotinib
(EGFR inhibitor), MK-0646 (IGF-1R inhibitor), or PHA-
665752 (MET inhibitor) with or without rapamycin 0.1 nM.
The results for MM cell line 211H are shown in Figure 9, and
the results for all lines are summarized in (Supplementary
Table 3, http://links.lww.com/JTO/A74). As described earlier,
sensitivity to erlotinib varies, with five moderately sensitive cell
lines (IC50 between 2.5 and 6 M) and eight resistant cell lines
among the 13 cell lines. In combination with rapamycin 0.1 nM,
the IC50 for erlotinib was considerably decreased for six cell
lines, moderately decreased for three cell lines and unchanged
for four cell lines. At an erlotinib concentration of 1.25 M,
the combination of rapamycin 0.1 nM  erlotinib was more
active than either drug alone for seven cell lines, two of
which also show reduced phospho-AKT by Western blot.
Similar results were observed for PHA-665752, with nine
moderately sensitive cell lines (IC50 between 3 and 7.5 M)
and four resistant cell lines. The combination of PHA-665752
1.25 M with rapamycin 0.1 nM significantly reduces pro-
liferation in six cell lines, two of which show reduced
phospho-Akt expression. The 13 cell lines were relatively
resistant to IGF-1R inhibition (IC50s 15 M), but the
combination of MK-0646 15 Mwith rapamycin 0.1 nM was
more effective than either drug alone for six cell lines with
associated decrease of phospho-AKT in four of six cell lines.
The 211H cell line was sensitive to all combinations therapies
(Figure 9), whereas only one cell line, H-Meso, was resistant
to all combination therapies. This cell line does not show any
AKT feedback activation after treatment with rapamycin; it
also shows no evidence of NF2 loss (Supplementary Table 2,
FIGURE 5. Phospho-RTK arrays
were performed before and after
administration of rapamycin 0.1
nM for 6 hours. This increased the
expression of selected phospho-
RTKs, such as p-EGFR in the H2052
line (A), p-MET in the H-Meso1A
line (B), and p-IGF1R in the 211H
cell line (C). Phospho-RTK, phos-
phorylated receptor tyrosine ki-
nases; p-EGFR, phosphorylated
EGFR; p-MET, phosphorylated MET;
p-IGF1R, phosphorylated IGF1R.
FIGURE 6. Phospho-AKT expres-
sion increases after treatment with
rapamycin 0.1 nM in H2452 cells.
The AKT feedback activation disap-
pears when cells are cultured in
medium lacking FCS (FCS). In
contrast, there is no AKT feedback
activation in the VAMT cell line.
Phospho-AKT, phosphorylated AKT;
FCS, fetal calf serum.
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http://links.lww.com/JTO/A74). Conversely, there were three
“NF2 intact” cell lines (no NF2 loss by CGH array, no NF2
mutation, and normal NF2 protein expression) that were none-
theless sensitive to rapamycin, being 211H, H28, and H2452
(Supplementary Table 2, http://links.lww.com/JTO/A74). For
these lines, the sensitivity to rapamycin could be due to other
mechanisms.
DISCUSSION
In this study, we confirmed the coactivation of MET
and EGFR in most cases of pleural MM, and we describe, for
the first time, the codependence of the EGFR and MET
signaling in MM. MET expression in MM has been previ-
ously documented21,22 and its coexpression with EGFR in
MM.17,21 Cross-activation of these two RTKs has been ob-
served in human glioma cells19,31 but has not been reported in
MM. In this study, we provide support for a significant
crosstalk between EGFR and MET in MM cells by showing
a decrease in phospho-EGFR on treatment with either MET
inhibitor or MET siRNA, an increase of phospho-EGFR on
HGF stimulation, an increase in phospho-MET on EGF
stimulation, and enhanced MM cell growth inhibition by
combination targeting of these two RTKs. PHA-665752 is
known to exhibit very high selectivity for MET relative to
other tested kinases, and its biochemical IC50s of MET and
EGFR are 0.009 M and 3.8 M, respectively.32 This sug-
gests that the observed effects of PHA-665752 on p-EGFR
levels may be at least partly indirect, most likely through
MET, a scenario further supported by MET knockdown by
RNA interference. Furthermore, in EGFR-mutant lung can-
cers, acquired MET amplification can contribute to secondary
resistance to EGFR TKIs.30,33 Together, these data suggest
that MET activation in MM may account for the poor re-
sponse to EGFR inhibitors alone in this disease.20,21 Finally,
Perrone et al.16 recently described a cross-activation of EGFR
and PDGFR in MM tumors. Of our 13 cell lines, only the
Meso 56 cell line showed evidence of PDGFR signaling, in
the form of slight activation of PDGFR after treatment with
rapamycin.
Our results show autocrine HGF production by the
JMN cell line consistent with previous data.22 This is an
uncommon mechanism of MET activation in MM; combining
the present with previous similar cell line studies,22 only two
of 20 MM lines (10%) show this autocrine loop. As also
noted by others,22 JMN is sensitive to MET inhibition. The
coexpression HGF/MET was also observed in MM tumor
samples but in a lower proportion (10%) than in a previous
report.11 That may reflect more stringent scoring criteria used
in this study. The proportion of 10% is also more consistent
with the above cell line data.
MET somatic mutations are rare in MM, occurring in at
most 3% (2/70) of cases and, therefore, cannot account for the
high frequency of MET activation in this cancer. Mukohara et
al.22 and Kawaguchi et al.21 found no activating mutations in
MET in 10 and 20 cell lines, respectively. In contrast, Jag-
adeeswaran et al.23 reported that cells harboring the T1010I
variant exhibited a more marked reduction of cell growth
with the MET inhibitor SU11274. In this study, the VAMT
FIGURE 7. Combination therapy
with MET and EGFR inhibitors in six
MM lines (JMN, H-Meso, Meso9,
Meso10, VAMT, and 211H). Erlo-
tinib had no effect on MM cells
(IC50 10 M) except for JMN
cells that were slightly inhibited by
erlotinib (IC50: 10 M). In JMN,
Meso 10, and Meso 9, the two
drugs in combination inhibited cell
growth more than PHA-665752
alone. MET, HGF receptor; EGFR,
epidermal growth factor receptor;
MM, malignant mesothelioma; IC50,
inhibitory concentration 50%.
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cell line with T1010I was not more sensitive to PHA-665752
than other MM cell lines. MET T1010I was recently shown to
transform IL-3 dependent BA/F3 cells.34 Tengs et al.35 de-
tected the MET T1010I polymorphism in 5 of 361 lung
cancer samples (1.4%), but not in any of 180 healthy indi-
viduals, and, therefore, proposed that this germline variant
may increase the risk of cancer development. We found the
MET T1010I polymorphism in 3 of 70 MM cases (4.3%);
further work is needed to determine whether this polymor-
phism could be a risk factor for MM.
The cross-activation between the EGFR and MET sug-
gests that inhibition of only one of the two kinases is unlikely
to be effective and that combination therapy should be con-
sidered. This notion is also supported by recent data in
gliomas, where two groups36,37 have shown that, because
multiple RTKs are coactivated, combinations of RTK inhib-
itors decreased signaling and cell survival more effectively.
Our results show a better efficacy of dual inhibition of EGFR
and MET in four of six cell lines. This was also observed by
Kawaguchi et al.21 in five other MM cell lines.
The PI3K/Akt/mTOR pathway plays an important role
in carcinogenesis, but inhibition of mTOR by rapamycin is
complicated by a feedback activation of AKT triggered by
release of negative feedback from mTOR to RTKs.28,38,39 To
confirm that the AKT pathway is activated by loss of negative
feedback at the level of RTKs on rapamycin treatment, we
used combination therapy for rapamycin and RTK inhibitors.
In this study, we show that this AKT activation is also present
in MM cell lines after treatment with rapamycin 0.1 nM. We
identified EGFR, MET, and IGF1R as the RTKs possibly
involved in this AKT feedback activation. Given our results
above and previous data, EGFR and MET were perhaps not
unexpected. IGF1R activation is present in some MM lines in
our panel and has been previously described in MM cell
lines.18–20 We find that the combination of rapamycin and one
specific RTK inhibitor decreases proliferation in 12 of 13 cell
lines. Nevertheless, the RTK involved varies from one cell
line to another. Combination treatment with mTOR and RTK
inhibitors has been studied in many cancers, including AML
(rapamycin  IGF1R inhibitor, Ref. 39), glioblastomas
FIGURE 8. Western blot after administration of PHA-665752 (10 M), erlotinib (10 M), or the combination. In all four lines, the
combination of the two inhibitors showed a synergistic effect on levels of phosphorylated MET and EGFR in comparison with either
alone. In the two cell lines sensitive to the combination therapy (JMN and Meso 9), the drug combination also decreased both
p-AKT and p-ERK. In contrast, the combination did not reduce p-AKT and p-ERK at all in the H-Meso cell line and only slightly in
the VAMT line. MET, HGF receptor; EGFR, epidermal growth factor receptor; p-AKT, phosphorylated AKT; p-ERK, phosphorylated ERK.
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FIGURE 9. The 211H cell line was sensitive to all combination therapies. The combination of rapamycin 0.1 nM with either
erlotinib 1.25 M (A), PHA-665752 1.25M (B), or MK-0646 15M (C) is more efficient than either drug alone. By Western
blot, phospho-AKT expression is increased by rapamycin, strongly decreased by PHA-665752 (B), and slightly decreased by
erlotinib and MK-0646 (B and C). *p less than 0.05, **p less than 0.005.
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(rapamycin  EGFR inhibitor, Ref. 40), and sarcomas (rapa-
mycin  IGF1R inhibitor, Ref. 28) and always shows a
significant decrease in proliferation compared with either
drug alone.
In conclusion, our data confirm the frequent coexpres-
sion of MET and EGFR in MM cell lines and tumors, and we
show, for the first time, evidence for cross-activation between
these two RTKs in MM. JMN, the only MM cell line in this
study with evidence of a MET/HGF autocrine loop, exhibited
the most dramatic reduction of cell growth in response to
single-agent MET inhibition and to combined MET and
EGFR inhibition. Identifying the subset of MM cases that
may be driven at least in part by a MET/HGF autocrine loop
may have relevance beyond MET-directed therapy. The con-
comitant activation of several RTKs may allow tumor cells to
acquire resistance to TKI monotherapies,17 and combination
of RTKs inhibitors may, therefore, be necessary in MM.
Furthermore, at treatment by the mTOR inhibitor, rapamycin
induces AKT feedback activation in most MM cell lines,
activation which is mediated by various RTKs, including
MET, EGFR, and IGF1R. Combination targeting of mTOR
and specific RTKs suppresses AKT pathway activation and
more effectively decreases cell growth.
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